ATE223386T1 - Benzimidazol-derivate und ihre verwendung als corticotropin freisetzenden faktor antagonisten - Google Patents

Benzimidazol-derivate und ihre verwendung als corticotropin freisetzenden faktor antagonisten

Info

Publication number
ATE223386T1
ATE223386T1 AT97304006T AT97304006T ATE223386T1 AT E223386 T1 ATE223386 T1 AT E223386T1 AT 97304006 T AT97304006 T AT 97304006T AT 97304006 T AT97304006 T AT 97304006T AT E223386 T1 ATE223386 T1 AT E223386T1
Authority
AT
Austria
Prior art keywords
benzimidazole derivatives
releasing factor
corticotropin releasing
factor antagonists
antagonists
Prior art date
Application number
AT97304006T
Other languages
English (en)
Inventor
Robert A Volkmann
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE223386T1 publication Critical patent/ATE223386T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT97304006T 1996-06-11 1997-06-10 Benzimidazol-derivate und ihre verwendung als corticotropin freisetzenden faktor antagonisten ATE223386T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1958796P 1996-06-11 1996-06-11

Publications (1)

Publication Number Publication Date
ATE223386T1 true ATE223386T1 (de) 2002-09-15

Family

ID=21793991

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97304006T ATE223386T1 (de) 1996-06-11 1997-06-10 Benzimidazol-derivate und ihre verwendung als corticotropin freisetzenden faktor antagonisten

Country Status (9)

Country Link
US (1) US6022978A (de)
EP (1) EP0812831B1 (de)
JP (1) JP3323420B2 (de)
AT (1) ATE223386T1 (de)
CA (1) CA2207348C (de)
DE (1) DE69715097T2 (de)
DK (1) DK0812831T3 (de)
ES (1) ES2181995T3 (de)
PT (1) PT812831E (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094782B1 (en) 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US6124289A (en) * 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
JP2001511813A (ja) 1997-02-18 2001-08-14 ニューロクライン バイオサイエンシーズ，インコーポレイテッド Ｃｒｆレセプターアンタゴニストおよびそれらに関連する方法
JP2002507996A (ja) * 1997-07-03 2002-03-12 デュポン ファーマシューティカルズ カンパニー 神経学的障害を治療するためのイミダゾピリミジン類およびイミダゾピリジン類
US6124463A (en) * 1998-07-02 2000-09-26 Dupont Pharmaceuticals Benzimidazoles as corticotropin release factor antagonists
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
KR20030016222A (ko) * 2000-02-14 2003-02-26 니뽄 다바코 산교 가부시키가이샤 수술후 스트레스 예방ㆍ치료제
US6888004B2 (en) 2001-01-26 2005-05-03 Bristol-Myers Squibb Company Imidazolyl derivatives as corticotropin releasing factor inhibitors
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
BR0209252A (pt) 2001-04-27 2004-07-20 Eisai Co Ltd Pirazolo[1,5-a]piridinas e medicamentos contendo as mesmas
US7176216B2 (en) 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
AU2003275589B2 (en) 2002-10-22 2009-05-28 Eisai R & D Management Co., Ltd. 7-phenyl pyrazolopyridine compounds
WO2004080975A1 (ja) * 2003-03-13 2004-09-23 Idemitsu Kosan Co., Ltd. 新規含窒素複素環誘導体及びそれを用いた有機エレクトロルミネッセンス素子
MY152687A (en) 2008-04-15 2014-10-31 Eisai R&D Man Co Ltd 3-phenylpyrazolo[5,1-b]thiazole compound
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5140055A (en) * 1986-07-01 1992-08-18 Bridgestone Corporation Rubber composition
US5063245A (en) * 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
TW336932B (en) * 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
US5646152A (en) * 1994-06-15 1997-07-08 Pfizer Inc. Methods of administering CRF antagonists
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists

Also Published As

Publication number Publication date
DK0812831T3 (da) 2002-10-07
DE69715097D1 (de) 2002-10-10
DE69715097T2 (de) 2003-01-02
US6022978A (en) 2000-02-08
MX9704299A (es) 1998-06-30
PT812831E (pt) 2002-12-31
JPH1072449A (ja) 1998-03-17
JP3323420B2 (ja) 2002-09-09
CA2207348A1 (en) 1997-12-11
EP0812831A1 (de) 1997-12-17
CA2207348C (en) 2001-08-21
ES2181995T3 (es) 2003-03-01
EP0812831B1 (de) 2002-09-04

Similar Documents

Publication Publication Date Title
DE69715097D1 (de) Benzimidazol-derivate und ihre Verwendung als Corticotropin freisetzenden Faktor Antagonisten
DK0616807T3 (da) Benzimidazol anvendelig i behandlingen af forstyrrelser i centralnervesystemet
NO965237L (no) Corticotropin-frigjörende faktor-antagonister
MA26914A1 (fr) Derives bicycliques substitues pour le traitement d'une croissance cellulaire anormale
ATE229334T1 (de) Verwendung von crf-antagonisten
DE69129009D1 (de) Indole Derivate als Serotonin-Antagonisten
FI935555A0 (fi) Nya sulfonamider
ATE438630T1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
ES2188242T3 (es) Derivados de quinolina.
ES2181853T3 (es) Tratamiento del tinnitus empleando agentes neuroprotectores.
ATE230392T1 (de) Amidinophenyl-pyrrolidine, -pyrroline und - isoxazolidine und ihre derivate
NO941884D0 (no) 1,3-substituerte cykloalkener og cykloalkaner som sentralnervesystem-midler
FI932035A0 (fi) Tricykliska foereningar innehaollande heteroatomer
FI920734A0 (fi) Ketosyror innehaollande kinoliner med leukotrienantagonisteffekt.
FI970469A0 (fi) Bentsimidatsolijohdannaisia, joilla on dopaminerginen aktiivisuus
ES2102772T3 (es) Compuesto citotoxico y antiviral.
FI930236A0 (fi) Bensimidazoler, dessa foereningar innehaollande laekemedel och foerfarandefoer deras framstaellning
DE69228307D1 (de) Imidazo(1,2-c)chinazolinderivate als antihypertensive und antidysurie
PT896822E (pt) 4-aminopirrolo (3,2-d)pirimidinas como antagonistas do receptor de neuropeptideo y
NO20003629D0 (no) Forbindelser med veksthormonfrigjørende egenskaper
NO993372D0 (no) Substituerte 4-(6-fluor-(1H)-indol-3-yl)-1,2,3,6-tetrahydropyridin for behandling av CNS-forstyrrelser
ITRM930498A0 (it) Imminoeteri originali, loro preparazione e loro impiego come stabilizzanti per materiali polimerici contro l'azione della luce.
PT889044E (pt) Derivados do 5-(heteroaril)alquil-3-oxo-pirido-(1,2-a)benzimidazole-4-carboxamida (pbi) uteis no tratamento de perturbacoes do sistema nervoso central
DE69932627D1 (de) Iminoguanidine derivate, ihre herstellung und verwendung als arzneimittel
MX9606198A (es) Antagonistas de factor de liberacion de corticotropina.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee